loader2
Login Open ICICI 3-in-1 Account
  • Text Size
  • Text to Speech
  • Color Contrast
  • Pause Animations

Open ICICI
3-in-1 Account

Manage your Savings, Demat and Trading Account conveniently at one place

+91

BLOG

USFDA for its recent inspection of Aurobindo's Eugia Unit III

ICICIdirect Research 15 Jun 2026 DISCLAIMER

News: USFDA for its recent inspection of Aurobindo's Eugia Unit III (Formulation manufacturing facility) has determined the inspection classification of this facility as official action indicated. The plant covers injectables and ophthalmic. The classification suggests another eminent warning letter.

View: This plant has 35 pending approvals and it has been under compliance review for some time now. Earlier company decided to temporarily stop manufacturing on certain lines to conduct holistic investigation and corresponding partial distribution thereto. This could lead to some negative impact on the overall margins as the company might have to undertake certain remediation measures. This might also lead to revenue postponement of the pending approvals, but as the company is going to consolidate US based Lanett from Q2FY27, the overall impact is expected to be minimal. Overall, despite undertaking calibrated de-risking initiatives (Pen G, Biosimilars, Biologics CMO) recurring plant-compliance related issues may weigh on sentiments in the near term.

Impact: Negative

Download ICICI Direct app

Invest, Track, and Manage your Portfolio Anytime, Anywhere

Download ICICI Direct app

Invest, Track, and Manage your Portfolio Anytime, Anywhere